Genetic Staging of Unresectable or Metastatic Neuroblastomain Infants: a Pediatric Oncology Group Study (original) (raw)

Journal Article

Laura C. Bowman ,

Department of Hematology-Oncology, St. Jude Children's Research Hospital, and Department of Pediatrics, University of Tennessee

,

Memphis

Correspondence to: Laura C. Bowman, M.D., Department of Hematology-Oncology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105-2794.

Search for other works by this author on:

Robert P. Castleberry ,

Department of Pediatrics, University of Alabama

,

Birmingham

Search for other works by this author on:

Alan Cantor ,

Moffitt Cancer Center and Research Institute, Cancer Control

,

Tampa, FL

Search for other works by this author on:

Vijay Joshi ,

Department of Pathology, East Carolina University

,

Greenville, NC

Search for other works by this author on:

Susan L. Cohn ,

Children's Memorial Hospital and Department of Pediatrics, Northwestern University

,

Chicago, IL

Search for other works by this author on:

E. Ide Smith ,

Smith, Southwestern Medical Center and Department of Pediatric Surgery, University of Texas

,

Dallas

Search for other works by this author on:

Alice Yu ,

Department of Pediatrics, University of California

,

San Diego

Search for other works by this author on:

Garrett M. Brodeur ,

Division of Oncology, Children's Hospital of Philadelphia

,

PA

Search for other works by this author on:

F. Ann Hayes ,

Immunex Corporation

,

Seattle, WA

Search for other works by this author on:

A. Thomas Look

Department of Experimental Oncology and Department of Hematology-Oncology, St. Jude Children's Research Hospital, and Department of Pediatrics, University of Tennessee

Search for other works by this author on:

Received:

12 September 1996

Revision received:

23 December 1996

Accepted:

03 January 1997

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Laura C. Bowman, Robert P. Castleberry, Alan Cantor, Vijay Joshi, Susan L. Cohn, E. Ide Smith, Alice Yu, Garrett M. Brodeur, F. Ann Hayes, A. Thomas Look, Genetic Staging of Unresectable or Metastatic Neuroblastomain Infants: a Pediatric Oncology Group Study, JNCI: Journal of the National Cancer Institute, Volume 89, Issue 5, 5 March 1997, Pages 373–380, https://doi.org/10.1093/jnci/89.5.373
Close

Navbar Search Filter Mobile Enter search term Search

Extract

Background: Current staging systems for unresectable or metastatic neuroblastoma do not reliably predict responses to chemotherapy in infants under 1 year of age. Previous studies have indicated that the DNA content, or ploidy, of malignant neuroblasts can discriminate between good and poor responders in this group of patients, but the clinical utility of ploidy assessment has remained in question. Purpose: We tested, in a prospective nonrandomized study, the hypothesis that neuroblast ploidy could be used as the sole guide for treatment selection in infants with unresectable or metastatic tumors and could differentiate between those who would respond to our previous standard regimen and those who would benefit from an immediate switch to another therapy. Methods: One hundred seventy-seven infants were enrolled in this trial. Five of these infants were subsequently excluded (two ineligible, two lacking ploidy information, and one protocol violation); therefore, 172 patients were included in the study. One hundred thirty infants with hyperdiploid tumors (DNA index > 1.0; better prognosis in retrospective studies) were treated with a well-tolerated regimen of cyclophosphamide (150 mg/m 2 per day orally or intravenously ondays 1–7) and doxorubicin (35 mg/m 2 intravenously on day 8). Forty-two infants with diploid tumors (DNA index = 1.0; worse prognosis in retrospective studies) received cisplatin (90 mg/m 2 intravenously on day 1) and teniposide (100 mg/m 2 intravenously on day 3) after an initial course of cyclophosphamideplus doxorubicin. Statistical end points were response and long-term survival. In addition, we assessed within each ploidy group (i.e., patients with hyperdiploid tumors and those with diploid tumors) the prognostic significance of NMYC gene copy number, tumor stage, and other variables commonly measured in this disease. Results: Of the 127 assessable infants with hyperdiploid tumors, 115 (91%) had complete responses—85 after receiving five courses of cyclophosphamide plus doxorubicin and 30 after receiving further therapy including cisplatin plus teniposide. The 3-year survival estimate for the entire hyperdiploid group was 94% (95% confidence interval [CI] = 89%–98%). Nineteen (46%) of 41 assessable infants with diploid tumors were complete responders. The overall 3-year survival estimate for this group was 55% (95% CI = 39%–70%). Prognostic factor analysis indicated that NMYC gene amplification and an elevated serum lactate dehydrogenase level were statistically significant markers of higher risk disease within the diploid group (two-sided P values of .005 and .003, respectively). Only NMYC was predictive in the hyperdiploidgroup ( P = .003). Conclusion: Use of a prognostic staging system based on tumor cell ploidy, augmented with the NMYC gene copy number and serum level of lactate dehydrogenase,would very likely improve the treatment of infants with unresectable or metastatic neuroblastoma. Patients with diploid tumors characterized by an amplified NMYC locus represent a particularly unfavorable risk group that may benefit from innovative new therapies. [JNatl Cancer Inst 1997;89:373–80]

Topic:

• diploidy
• infant
• genetics
• neoplasms
• pediatric oncology
• group trial

You do not currently have access to this article.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Genetic Staging of Unresectable or Metastatic Neuroblastomain Infants: a Pediatric Oncology Group Study - 24 Hours access

EUR €39.00

GBP £33.00

USD $43.00

Rental

This article is also available for rental through DeepDyve.